/NBIO
NBIO Stock - Nascent Biotech, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.56
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.59
52W High$0.13
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $1.00M | $750,000 | N/A |
| Gross Profit | $-320,000 | N/A | $1.00M | $750,000 | N/A |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | N/A |
| Operating Income | $-2,230,000 | $-2,156,000 | $-457,000 | $-1,400,000 | $-3,447,000 |
| Net Income | $-2,088,000 | $-2,801,000 | $-470,000 | $-959,000 | $-4,004,153 |
| Net Margin | N/A | N/A | -47.0% | -127.9% | N/A |
| EPS | $-0.01 | $-0.02 | $-0.00 | $-0.01 | $-0.12 |
Company Overview
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NBIOBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q4 2024
EPS Surprise History
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q3 24
No data
Q3 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 30, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Feb 28, 2025 | — | — | — | — |
Q4 2024 | Nov 18, 2024 | — | $-0.00 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.00 | — | — |
Q3 2024 | Jul 1, 2024 | — | $-0.00 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-0.00 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.01 | — | — |
Q3 2023 | Aug 18, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 29, 2023 | — | $-0.00 | — | — |
Q1 2023 | Feb 14, 2023 | — | $-0.01 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 9, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 15, 2022 | — | $-0.00 | — | — |
Q1 2022 | Feb 14, 2022 | — | $0.01 | — | — |
Q4 2021 | Nov 4, 2021 | — | $-0.00 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-0.00 | — | — |
Q3 2021 | Jul 8, 2021 | — | $0.01 | — | — |
Q1 2021 | Feb 9, 2021 | — | $-0.01 | — | — |
Q4 2020 | Nov 16, 2020 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NBIO
What is NBIO's current stock price?
Nascent Biotech, Inc. (NBIO) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for NBIO?
No analyst price targets are currently available for this stock.
What sector is Nascent Biotech, Inc. in?
Nascent Biotech, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is NBIO's market cap?
Nascent Biotech, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does NBIO pay dividends?
No, Nascent Biotech, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBSYI
BioSyntech, Inc.
$0.00
Mkt Cap: $0.0B
CHNXF
ChitogenX Inc.
$0.01
Mkt Cap: $0.0B
CWWBF
Plant-Based Investment Corp.
$0.00
Mkt Cap: $0.0B
FCHS
First Choice Healthcare Solutions, Inc.
$0.01
Mkt Cap: $0.0B
PZOO
Pazoo, Inc.
$0.00
Mkt Cap: $0.0B
RASP
Actavia Life Sciences, Inc.
$0.00
Mkt Cap: $0.0B
RGRX
RegeneRx Biopharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
RLBD
Real Brands, Inc.
$0.00
Mkt Cap: $0.0B
VIVXF
Avivagen Inc.
$0.00
Mkt Cap: $0.0B
WSNAF
Wesana Health Holdings Inc.
$0.01
Mkt Cap: $0.0B
Explore stocks similar to NBIO for comparison